Member Info for Soupdragon78

Good Dan back at the ERS this year, the presentation looks good, not that I understand any of it.

MrHumble

Posts: 4,160

Price: 0.095

No Opinion

RE: MrHumble. 1 Sep 2025 20:02

Lets make it very clear then

News here in the next 1-10 market days. Most likely closer to 1 than 10.

It will be great news.

Lol. you're too small time for me MrHumble. You stick to your 50 quid trades.

Well done MrHumble to go from 'news is confirmed for this week' to 'will there be news' is quite a turn around, almost like you don't know what your talking about.

Welcome back Dansey, it’s what exactly a month since your last post.

We all know they need funding, that’s well documented by the company. They’ll need about £3m if they want to do the next phase of clinical.

Don’t worry yourself about whether they should focus on something else other than NXP002, that’s not going to happen, they’ll shut up shop if 02 goes no further.

So it’s nice and binary. It’s this or nothing.

Don't worry, MrHumble says news is confirmed for this week.

Good points Jiving, also watch out for those opening facilities in the UK, especially in certain locations.

Other conferences this month are

Wells Fargo Healthcare Conference in Boston (Today)

Cantor Global Healthcare Conference (New York) (Yesterday)

H.C. Wainwright 27th Annual Global Investment Conference (New York) (Next Tuesday)

Ah there you are... clocks ticking.

Old MrHumble is very quiet on here these days as we reach halfway into his 10 day prediction. He's posted 300 times elsewhere since his last post here, almost like he was never actually interested.

IPF shares doing well today off the back of United Therapeutics successful clinical trials of their Inhaled Tyvaso product.

Then why change your name MrHumble?

Lol beginner Mr Humble, yet on other threads you’re posting how you’ve been on LSE for years.

You Averaging 50 posts a day tells us something.

You're the one missing them FX, the company isn't.

Lighten up old boy, one day you'll understand.

Ok a bit of fun now....

How much would you pay for a London based Pharma company that has no revenues, no approved product and was only in Phase 1 with its product?

Well Sanofi's answer to this is buying ViceBio for $1.15bn up front!!! plus $450m in milestone payments!!! so up to $1.65bn on total!!!

https://www.fiercebiotech.com/biotech/sanofi-tightens-grip-rsv-inking-16b-vicebio-buyout-expand-pipeline-beyond-mrna

They are keen on the tech rather than the individual product.

Yes, its not related or comparable to what NFX are doing, but nice to see anyway.

Just like saying ‘where are the partners’

Why say it

As I said FX it may not be relevant.

It may be that the 9 April rns has become a little bit more relevant. (Or… it may not have)

No. Because the directors receive a percentage of any out licensing deal undertaken.

If the company went into administration then they would get nothing from and auction. Hence it’s not in their interest.

Pjm, the 1.9bn share figure is from the last placing at the end of May.

FDA will be fine and has thankfully nothing to do with the idiot manchild that is RFK Jr.

1,995,709,368 shares in issue, at 0.085p gives Mcap of circa £1.7m